NYSE:RDY - Dr.Reddy's Laboratories Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $40.54 +0.52 (+1.30 %) (As of 03/26/2019 12:04 PM ET)Previous Close$40.02Today's Range$40.43 - $40.5752-Week Range$28.13 - $40.84Volume1,199 shsAverage Volume177,884 shsMarket Capitalization$6.73 billionP/E Ratio40.05Dividend Yield0.69%Beta0.1 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Receive RDY News and Ratings via Email Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RDY Previous Symbol CUSIPN/A CIK1135951 Webwww.drreddys.com Phone91-40-4900-2900Debt Debt-to-Equity Ratio0.18 Current Ratio1.81 Quick Ratio1.26Price-To-Earnings Trailing P/E Ratio40.05 Forward P/E Ratio26.67 P/E GrowthN/A Sales & Book Value Annual Sales$2.20 billion Price / Sales3.05 Cash Flow$2.1644 per share Price / Cash Flow18.73 Book Value$11.71 per share Price / Book3.46Profitability EPS (Most Recent Fiscal Year)$1.01 Net Income$151 million Net Margins11.64% Return on Equity13.16% Return on Assets7.52%Miscellaneous Employees23,524 Outstanding Shares166,040,000Market Cap$6.73 billion Next Earnings Date5/28/2019 (Estimated) OptionableOptionable Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions What is Dr.Reddy's Laboratories' stock symbol? Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY." How were Dr.Reddy's Laboratories' earnings last quarter? Dr.Reddy's Laboratories Ltd (NYSE:RDY) released its earnings results on Friday, February, 1st. The company reported $0.41 earnings per share for the quarter. The company earned $535.42 million during the quarter. Dr.Reddy's Laboratories had a return on equity of 13.16% and a net margin of 11.64%. View Dr.Reddy's Laboratories' Earnings History. When is Dr.Reddy's Laboratories' next earnings date? Dr.Reddy's Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, May 28th 2019. View Earnings Estimates for Dr.Reddy's Laboratories. What is the consensus analysts' recommendation for Dr.Reddy's Laboratories? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dr.Reddy's Laboratories. Has Dr.Reddy's Laboratories been receiving favorable news coverage? Media headlines about RDY stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dr.Reddy's Laboratories earned a news impact score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Dr.Reddy's Laboratories' key competitors? Some companies that are related to Dr.Reddy's Laboratories include UCB (UCBJF), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE) and Beigene (BGNE). What other stocks do shareholders of Dr.Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dr.Reddy's Laboratories investors own include Infosys (INFY), Vedanta (VEDL), GlaxoSmithKline (GSK), HDFC Bank (HDB), Siemens (SIEGY), Tata Motors (TTM), Novo Nordisk A/S (NVO), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN) and Allergan (AGN). Who are Dr.Reddy's Laboratories' key executives? Dr.Reddy's Laboratories' management team includes the folowing people: Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 59)Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 52)Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 58)Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 50)Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 56) Who are Dr.Reddy's Laboratories' major shareholders? Dr.Reddy's Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.19%), Commonwealth Bank of Australia (1.04%), Dimensional Fund Advisors LP (0.56%), Dimensional Fund Advisors LP (0.56%), Mondrian Investment Partners LTD (0.35%) and Northern Trust Corp (0.25%). Which institutional investors are selling Dr.Reddy's Laboratories stock? RDY stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, NINE MASTS CAPITAL Ltd, Commonwealth Bank of Australia, Mondrian Investment Partners LTD, Zurcher Kantonalbank Zurich Cantonalbank, Geode Capital Management LLC, Geode Capital Management LLC and Bank of Montreal Can. Which institutional investors are buying Dr.Reddy's Laboratories stock? RDY stock was acquired by a variety of institutional investors in the last quarter, including Charles Lim Capital Ltd, BlackRock Inc., Macquarie Group Ltd., ClariVest Asset Management LLC, New Vernon Capital Holdings II LLC, Prudential Financial Inc., Tekla Capital Management LLC and Henry James International Management Inc.. How do I buy shares of Dr.Reddy's Laboratories? Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dr.Reddy's Laboratories' stock price today? One share of RDY stock can currently be purchased for approximately $40.52. How big of a company is Dr.Reddy's Laboratories? Dr.Reddy's Laboratories has a market capitalization of $6.73 billion and generates $2.20 billion in revenue each year. The company earns $151 million in net income (profit) each year or $1.01 on an earnings per share basis. Dr.Reddy's Laboratories employs 23,524 workers across the globe. What is Dr.Reddy's Laboratories' official website? The official website for Dr.Reddy's Laboratories is http://www.drreddys.com. How can I contact Dr.Reddy's Laboratories? Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected] MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 310 (Vote Underperform)Total Votes: 541MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?